For research use only. Not for therapeutic Use.
Atomoxetine is a norepinephrine reuptake inhibitor approved for the treatment of attention deficit hyperactivity disorder (ADHD). The brand name is Strattera. The initial therapeutic effects of atomoxetine usually take 2–4 weeks to become apparent. There has been some suggestion that atomoxetine might be a helpful adjunct in people with major depression, especially in cases where ADHD occurs comorbidly to major depression.
| Catalog Number | A001162 |
| CAS Number | 82248-59-7 |
| Synonyms | LY 139603 HCl |
| Molecular Formula | C17H21NO.HCl |
| Purity | ≥95% |
| Target | Norepinephrine Reuptake Inhibitor |
| Storage | 3 years -20C powder |
| InChI | InChI=1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1 |
| InChIKey | LUCXVPAZUDVVBT-UNTBIKODSA-N |
| SMILES | CC1=CC=CC=C1O[C@@H](C2=CC=CC=C2)CCNC.[H]Cl |
| Reference | 1:J Pharm Sci. 2006 Aug;95(8):1677-83. Structural determination of the stable and meta-stable forms of atomoxetine HCl using single crystal and powder X-ray diffraction methods.Stephenson GA,Liang C, PMID: 16732589 DOI: 10.1002/jps.20643 </br><span>Abstract:</span> Stratteratrade mark is the first FDA-approved nonstimulant medication for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults. Two polymorphic forms and an amorphous form of the active pharmaceutical ingredient, atomoxetine HCl, were discovered during drug development. The thermodynamically stable polymorphic form was selected for the commercial product. The stable form readily grows as crystals suitable for single crystal diffraction. The meta-stable crystal form is isolated by rapid crystallization, providing crystals that are too small for routine single crystal methods; consequently its structure was determined by X-ray powder diffraction.Copyright 2006 Wiley-Liss, Inc. |
